Pfizer cancer drug Ibrance higher sales beat Q3 profit estimates Medical Dialogues Bureau30 Oct 2019 9:30 AM ISTPfizer said it expects to earn between $2.94 per share and $3.00 per share, up from a prior estimate of $2.76 to $2.86. Analysts on average were...
Novartis wins USFDA approval for first PI3K inhibitor for breast cancer Farhat Nasim27 May 2019 6:10 PM ISTThe drug, alpelisib, to be marketed under the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors and is the first of its kind to...
AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise Medical Dialogues Bureau10 May 2019 9:00 AM ISTThe treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
Emcure launches generic Eribulin at 40 percent lower price in India Farhat Nasim4 April 2019 9:30 AM ISTEmcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent...
Novartis takes fight to Pfizers Ibrance with new Kisqali data Ruby Khatun Khatun10 Nov 2017 10:17 AM ISTZURICH: New data from Novartis's breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid...
Lilly takes on Pfizer, Novartis with new breast cancer drug data Ruby Khatun Khatun12 Sept 2017 10:01 AM ISTNEW YORK/MADRID: Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its...
